Victoria’s Secret & Co. (NASDAQ:VSXY) stock has gained over 197% in the past 12 months, exceeding the performance of semiconductor exchange-traded funds.
This market movement aligns with Kylie Jenner walking in the company’s Oct. 18 fashion show and Needham analysts forecasting future gains tied to weight-loss medication trends.
Outpacing Tech Stocks
Trading under the symbol VSXY, the lingerie retailer has posted a one-year return of 197.16%. In comparison, the semiconductor ETFs iShares Semiconductor ETF (NASDAQ:SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL) have returned 74.18% and 144.85%, respectively, over the same period.
| Stocks | 1-Month | 6-Months | YTD | 1-Year | 5-Years |
| VSXY | 15.46% | 64.44% | 66.11% | 197.16% | 71.82% |
| SOXX | -5.84% | 20.74% | 64.61% | 74.18% | 224.90% |
| SOXL | -20.23% | 4.19% | 134.71% | 144.85% | 122.03% |
A Revived Image and Ticker
The stock performance follows the company’s decision to change its New York Stock Exchange ticker symbol from VSCO to VSXY on June 2. Hillary Super, Chief Executive Officer of Victoria’s Secret & Co., stated that the new ticker is “a marker of who we are today” and that “VSXY is recognizable and aligns with our strategy and the progress we’ve made.”
Super noted the company is “standing fully in our identity and committed to inspiring confidence, sparking joy and celebrating sexy in all its forms.” Its brand momentum was recently visible when Jenner walked as an Angel in the Victoria’s Secret fashion show on Sunday night.
The GLP-1 Factor
Financial firm Needham initiated coverage of VSXY on Oct. 16, assigning the stock a ‘Buy’ rating and a price target of $106.00, representing a 17.80% upside from the current levels, according to the note shared by @AIStockSavvy on X. Analyst Tom Nikic noted that the company is in the “early innings of a multi-year turnaround” and projected that earnings per share could double over the next five years.
The firm also identified a specific consumer trend as a catalyst. Nikic wrote, “We believe VSXY can be a beneficiary of increased adoption of GLP-1 weight loss medicines (as slimmed-down women shop for new clothes and potentially put a greater emphasis on ‘sexiness’).” Needham concluded that VSXY is a “compelling momentum name heading into 2027.”
Benzinga’s Edge Stock Rankings indicate that VSXY maintains a strong price trend in the short, long, and medium terms, with a good growth score.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
Recent Comments